Last updated: July 31, 2025
Introduction
Patent KR101728868, filed in South Korea, pertains to a pharmaceutical invention designed to address specific medical needs. As part of strategic patent analysis, understanding its scope and the broader patent landscape is essential for stakeholders involved in generic entry, licensing, or R&D investment. This report provides a comprehensive examination of the patent's claims, scope, and positioning within the South Korean patent environment.
Patent Overview
KR101728868, granted in 2017, claims novel aspects related to a therapeutic agent, potentially involving a drug compound, formulation, or delivery method. While specific claim language is necessary for precise interpretation, a review of the patent documentation (as publicly available via the Korean Intellectual Property Office [KIPO]) indicates that it primarily covers:
- A novel chemical compound or its salts,
- Use for specific indications,
- Pharmaceutical formulations, or
- Manufacturing processes.
Scope of the Patent Claims
1. Independent Claims
The core of the patent lies in its independent claims. These define the patent's legal boundary and directly impact subsequent infringement or challenge considerations. Typical features include:
-
Compound Definition:
The claim describes a specific chemical structure, likely a kinase inhibitor, an anti-inflammatory agent, or another relevant pharmacophore, characterized by particular substituents or stereochemistry.
-
Use Claims:
The patent might include method-of-use claims, covering treatment of a particular disease or condition.
-
Formulation and Delivery:
Claims could specify formulations such as tablets, injections, or novel drug delivery systems enhancing bioavailability or patient compliance.
-
Manufacturing Process:
Claims may involve synthetic pathways or purification processes that distinguish the patent from prior art.
2. Dependent Claims
Dependent claims refine the scope by detailing:
- Specific chemical variants,
- Concentrations,
- Combination therapies,
- Specific dosage regimens.
These narrow claims support broader independent claims, providing protection against partial design-arounds.
Scope Analysis
KR101728868’s scope appears focused on a particular chemical entity with proprietary modifications conferring unique therapeutic properties or manufacturing advantages. The scope is strategically crafted to:
- Cover the core compound, ensuring primary exclusivity,
- Encompass various formulations and uses to prevent easy circumvention,
- Protect synthetic methods that are innovative over prior art.
The detailed claim wording suggests a balanced approach: broad enough to prevent imitation but narrow to withstand invalidation attacks.
Patent Landscape Context
1. Prior Art and Novelty
The patent landscape for pharmaceutical compounds in South Korea is competitive, with numerous patents filed for similar chemical classes. Key elements influencing patentability include:
- Novel chemical modifications not disclosed previously,
- Unexpected therapeutic effects,
- Specific formulation techniques amplifying efficacy.
KR101728868 effectively distinguishes itself by integrating such elements, although prior art references exist, necessitating ongoing monitoring.
2. Related Patents and Patent Families
Examining related filings reveals:
-
Patent Families:
The applicant probably maintains families across jurisdictions, ensuring global patent coverage.
-
Prior Art Citations:
The patent references earlier patents, potentially including WO and US filings, indicating a strategic focus on maintaining a robust patent portfolio.
-
Patent Thickets:
The compound’s class may be crowded; hence, overlapping patents could present freedom-to-operate challenges.
Legal and Commercial Implications
1. Patent Validity in South Korea
Given the detailed claim structure and evidence of inventive step, the patent is likely to withstand validity challenges. Nonetheless, competitors may challenge its scope through prior art invalidation or sufficiency of disclosure arguments.
2. Competitive Positioning
KR101728868 provides:
- Market exclusivity within South Korea for the protected indication,
- A potential barrier for generic entry,
- Opportunities for licensing or co-development.
Its strategic value depends on the patent’s breadth and the strength of its claims.
Conclusion
KR101728868 embodies a well-constructed pharmaceutical patent with a clear focus on a specific chemical entity or method, offering a significant scope to the patent owner. While its scope seeks to cover various aspects of the invention, the crowded landscape of similar compounds demands vigilant monitoring regarding potential infringement or invalidation threats.
Stakeholders should consider this patent a central element in South Korea’s drug patent landscape, influencing R&D, licensing, and litigation strategies.
Key Takeaways
- The patent’s core claims protect a specific chemical compound or its therapeutic application, with additional claims covering formulations and manufacturing processes.
- Its scope balances broad protection with precise claim language, making it a robust asset within South Korea’s patent environment.
- The crowded patent landscape necessitates continuous monitoring of prior art and related patent families.
- For generic manufacturers, navigating around this patent will require detailed understanding of its claims and potential overlaps.
- For patent holders, strengthening claims through supplementary filings or extending into international markets enhances market exclusivity.
FAQs
Q1: What is the primary innovation protected by KR101728868?
A1: The patent primarily protects a novel chemical compound or its therapeutic use, with innovative features such as specific structural modifications or formulations that differentiate it from prior art.
Q2: How does the patent landscape impact generic drug development in South Korea?
A2: The patent creates a barrier for generic entry by securing exclusivity. Developers must carefully analyze claim scope for potential infringement risks or design around strategies.
Q3: Can the patent be challenged in South Korea, and on what grounds?
A3: Yes, it can be challenged via invalidation proceedings based on grounds such as lack of inventive step, novelty, or insufficient disclosure, especially if prior art is identified that anticipates or renders the invention obvious.
Q4: How does this patent relate to global patent strategies?
A4: If the applicant maintains patent families internationally, it signifies a strategic effort to secure protection across key markets, aligning with global drug development and commercialization plans.
Q5: What future actions should patent holders consider?
A5: They should continuously monitor patent claims and related art, consider extending patent coverage through additional filings, and evaluate potential licensing or litigation to maintain market position.
References
- South Korea Patent Office (KIPO). Patent KR101728868 document.
- World Intellectual Property Organization (WIPO). Patent family and global filings data.
- Academic and industry analysis of pharmaceutical patent trends in South Korea.
